Aurinia Pharmaceuticals Inc.
Clinical trials sponsored by Aurinia Pharmaceuticals Inc., explained in plain language.
Biopharmaceutical company focused on lupus nephritis treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
Lupus kidney drug for teens shows promise, but trial cut short
Disease control Stopped earlyThis study tested a drug called voclosporin in teenagers with lupus nephritis, a kidney disease caused by lupus. The goal was to see if it could improve kidney function better than a placebo. Only 9 teens took part before the study was stopped early, so we don't have clear answer…
Phase 3 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Lupus kidney drug tested in kids – but study stopped early
Disease control Stopped earlyThis study looked at the long-term safety of the drug voclosporin in adolescents and children with lupus nephritis, a kidney disease caused by lupus. Participants took voclosporin capsules twice daily along with standard medications. The trial was terminated early and only enroll…
Phase 3 • Sponsor: Aurinia Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC